Oncogenic characterization and pharmacologic sensitivity of activating Fibroblast Growth Factor Receptor (FGFR) genetic alterations to the selective FGFR inhibitor erdafitinib

Molecular Cancer Therapeutics

Volumn 16, Issue 8, 2017, Pages 1717-1726

  Karkera, Jayaprakash D ^a   Cardona, Gabriela Martinez ^a   Bell, Katherine ^a   Gaffney, Dana ^a   Portale, Joseph C ^a   Santiago Walker, Ademi ^a   Moy, Christopher H ^a   King, Peter ^a   Sharp, Michael ^a   Bahleda, Rastislav ^b   Luo, Feng R ^c   Alvarez, John D ^a   Lorenzi, Matthew V ^a   Platero, Suso J ^a,d  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d 206 Carnegie Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERDAFITINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; PHOSPHATE; FIBROBLAST GROWTH FACTOR RECEPTOR; JNJ-42756493; ONCOPROTEIN; PYRAZOLE DERIVATIVE; QUINOXALINE DERIVATIVE; TUMOR MARKER;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CELL LINE; CANCER PATIENT; CANCER TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MIDDLE AGED; MULTIPLE CANCER; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BLADDER TUMOR; DIAGNOSTIC IMAGING; GENETICS; METABOLISM; NUDE RAT; ONCOGENE; PATHOLOGY; X-RAY COMPUTED TOMOGRAPHY;

ANIMALS; BIOMARKERS, TUMOR; MALE; ONCOGENE PROTEINS, FUSION; ONCOGENES; PYRAZOLES; QUINOXALINES; RATS, NUDE; RECEPTORS, FIBROBLAST GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED; URINARY BLADDER NEOPLASMS;

EID: 85027191137     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0518     Document Type: Article

References (36)

1. Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, et al. Trastuzumab and vinorelbine as first-line therapy for HER2-over-expressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 2003;21:2889–95.
2. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626–34.
3. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757–65.
4. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306–11.
5. Grande E, Bolos MV, Arriola E. Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol Cancer Ther 2011;10:569–79.
6. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013;22:795–803.
7. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001;2: REVIEWS3005.
8. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010;10:116–29.
9. Mohammadi M, Dikic I, Sorokin A, Burgess WH, Jaye M, Schlessinger J. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol Cell Biol 1996;16:977–89.
10. Plotnikov AN, Schlessinger J, Hubbard SR, Mohammadi M. Structural basis for FGF receptor dimerization and activation. Cell 1999;98:641–50.
11. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000;19:3309–20.
12. Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res 2008;68:2340–8.
13. Elbauomy Elsheikh S, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, et al. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 2007;9:R23.
14. Dodurga Y, Tataroglu C, Kesen Z, Satiroglu-Tufan NL. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer. Genet Mol Res 2011;10:86–95.
15. Kiemeney LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A, Thorleifsson G, et al. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet 2010; 42:415–9.
16. van Rhijn BW, van der Kwast TH, Liu L, Fleshner NE, Bostrom PJ, Vis AN, et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol 2012;187:310–4.
17. Jang JH, Shin KH, Park JG. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res 2001;61:3541–3.
18. Chang H, Stewart AK, Qi XY, Li ZH, Yi QL, Trudel S. Immunohistochem-istry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 2005;106:353–5.
19. Dvorak P, Dvorakova D, Doubek M, Faitova J, Pacholikova J, Hampl A, et al. Increased expression of fibroblast growth factor receptor 3 in CD34þ BCR-ABLþ cells from patients with chronic myeloid leukemia. Leukemia 2003;17:2418–25.
20. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2:62ra93.
21. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001;98:13784–9.
22. Turner NC, Seckl MJ. A therapeutic target for smoking-associated lung cancer. Sci Transl Med 2010;2:62ps56.
23. Network NCC. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 52015.
24. Freier K, Schwaenen C, Sticht C, Flechtenmacher C, Muhling J, Hofele C, et al. Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol 2007;43:60–6.
25. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012;337:1231–5.
26. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013;3:636–47.
27. Lorenzi MV, Horii Y, Yamanaka R, Sakaguchi K, Miki T. FRAG1, a gene that potently activates fibroblast growth factor receptor by C-terminal fusion through chromosomal rearrangement. Proc Natl Acad Sci U S A 1996;93:8956–61.
28. Majewski IJ, Mittempergher L, Davidson NM, Bosma A, Willems SM, Horlings HM, et al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol 2013; 230:270–6.
29. Wang R, Wang L, Li Y, Hu H, Shen L, Shen X, et al. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer. Clin Cancer Res 2014;20:4107–14.
30. Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol 2015;33:3401–8.
31. Yanochko GM, Vitsky A, Heyen JR, Hirakawa B, Lam JL, May J, et al. Pan-FGFR inhibition leads to blockade of FGF23 signaling, soft tissue mineralization, and cardiovascular dysfunction. Toxicol Sci 2013;135: 451–64.
32. Wohrle S, Henninger C, Bonny O, Thuery A, Beluch N, Hynes NE, et al. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res 2013;28:899–911.
33. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.
34. Pearson A, Smyth E, Babina IS, Herrera-Abreu MT, Tarazona N, Peckitt C, et al. High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. Cancer Discov 2016;6:838–51.
35. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res 2016;22:259–67.
36. Fischer H, Taylor N, Allerstorfer S, Grusch M, Sonvilla G, Holzmann K, et al. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther 2008;7:3408–19.